Last reviewed 2026-05-15 · How we verify

LMWH parnaparin subcutaneously

IRCCS Azienda Ospedaliero-Universitaria di Bologna · Phase 3 active Small molecule

LMWH parnaparin subcutaneously is a Low-molecular-weight heparin (LMWH) Small molecule drug developed by IRCCS Azienda Ospedaliero-Universitaria di Bologna. It is currently in Phase 3 development for Thromboembolism prophylaxis and treatment, Deep vein thrombosis prevention and treatment, Pulmonary embolism prevention and treatment.

Parnaparin is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.

Parnaparin is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis and treatment, Deep vein thrombosis prevention and treatment, Pulmonary embolism prevention and treatment.

Likelihood of approval

56.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LMWH parnaparin subcutaneously
Sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Drug class	Low-molecular-weight heparin (LMWH)
Target	Antithrombin III (indirect target); Coagulation factors Xa and IIa
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 3

Mechanism of action

Parnaparin works by potentiating antithrombin III-mediated inactivation of coagulation factors, particularly factor Xa (more than factor IIa), thereby preventing thrombin generation and fibrin clot formation. This anticoagulant effect is used to prevent and treat thromboembolism. The subcutaneous route provides predictable pharmacokinetics with a longer half-life compared to unfractionated heparin.

Approved indications

Thromboembolism prophylaxis and treatment
Deep vein thrombosis prevention and treatment
Pulmonary embolism prevention and treatment

Common side effects

Bleeding
Thrombocytopenia
Injection site reactions
Elevated transaminases

Key clinical trials

Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LMWH parnaparin subcutaneously CI brief — competitive landscape report
LMWH parnaparin subcutaneously updates RSS · CI watch RSS
IRCCS Azienda Ospedaliero-Universitaria di Bologna portfolio CI

Frequently asked questions about LMWH parnaparin subcutaneously

What is LMWH parnaparin subcutaneously?

LMWH parnaparin subcutaneously is a Low-molecular-weight heparin (LMWH) drug developed by IRCCS Azienda Ospedaliero-Universitaria di Bologna, indicated for Thromboembolism prophylaxis and treatment, Deep vein thrombosis prevention and treatment, Pulmonary embolism prevention and treatment.

How does LMWH parnaparin subcutaneously work?

Parnaparin is a low-molecular-weight heparin (LMWH) that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.

What is LMWH parnaparin subcutaneously used for?

LMWH parnaparin subcutaneously is indicated for Thromboembolism prophylaxis and treatment, Deep vein thrombosis prevention and treatment, Pulmonary embolism prevention and treatment.

Who makes LMWH parnaparin subcutaneously?

LMWH parnaparin subcutaneously is developed by IRCCS Azienda Ospedaliero-Universitaria di Bologna (see full IRCCS Azienda Ospedaliero-Universitaria di Bologna pipeline at /company/irccs-azienda-ospedaliero-universitaria-di-bologna).

What drug class is LMWH parnaparin subcutaneously in?

LMWH parnaparin subcutaneously belongs to the Low-molecular-weight heparin (LMWH) class. See all Low-molecular-weight heparin (LMWH) drugs at /class/low-molecular-weight-heparin-lmwh.

What development phase is LMWH parnaparin subcutaneously in?

LMWH parnaparin subcutaneously is in Phase 3.

What are the side effects of LMWH parnaparin subcutaneously?

Common side effects of LMWH parnaparin subcutaneously include Bleeding, Thrombocytopenia, Injection site reactions, Elevated transaminases.

What does LMWH parnaparin subcutaneously target?

LMWH parnaparin subcutaneously targets Antithrombin III (indirect target); Coagulation factors Xa and IIa and is a Low-molecular-weight heparin (LMWH).

Drug class: All Low-molecular-weight heparin (LMWH) drugs
Target: All drugs targeting Antithrombin III (indirect target); Coagulation factors Xa and IIa
Manufacturer: IRCCS Azienda Ospedaliero-Universitaria di Bologna — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Thromboembolism prophylaxis and treatment
Indication: Drugs for Deep vein thrombosis prevention and treatment
Indication: Drugs for Pulmonary embolism prevention and treatment

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing